Reduction of leukemic burden via bone‐targeted nanoparticle delivery of an inhibitor of C‐chemokine (C‐C motif) ligand 3 (CCL3) signaling
Marian A. Ackun‐Farmmer, Celia A. Soto, Maggie L. Lesch, Daniel Byun, Lila Yang, Laura M. Calvi, Danielle S. W. Benoit, Benjamin J. Frisch
Abstract
Abstract Leukemias are challenging diseases to treat due, in part, to interactions between leukemia cells and the bone marrow microenvironment (BMME) that contribute significantly to disease progression. Studies have shown that leukemic cells secrete C‐chemokine (C‐C motif) ligand 3 (CCL3), to disrupt the BMME resulting in loss of hematopoiesis and support of leukemic cell survival and proliferation. In this study, a murine model of blast crisis chronic myelogenous leukemia (bcCML) that expresses the translocation products BCR/ABL and Nup98/HoxA9 was used to determine the role of CCL3 in BMME regulation. Leukemic cells derived from CCL3 −/− mice were shown to minimally engraft in a normal BMME, thereby demonstrating that CCL3 signaling was necessary to recapitulate bcCML disease. Further analysis showed disruption in hematopoiesis within the BMME in the bcCML model. To rescue the altered BMME, therapeutic inhibition of CCL3 signaling was investigated using bone‐targeted nanoparticles (NP) to deliver Maraviroc, an inhibitor of C‐C chemokine receptor type 5 (CCR5), a CCL3 receptor. NP‐mediated Maraviroc delivery partially restored the BMME, significantly reduced leukemic burden, and improved survival. Overall, our results demonstrate that inhibiting CCL3 via CCR5 antagonism is a potential therapeutic approach to restore normal hematopoiesis as well as reduce leukemic burden within the BMME.